Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 EUR | +2.77% | 0.00% | -17.20% |
04-25 | Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024 | CI |
04-03 | Mauna Kea: first Italian center for Cellvizio | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.20% | 25.62M | - | ||
-12.91% | 19.08B | A | ||
-46.21% | 2.65B | C+ | ||
+18.15% | 1.87B | - | - | |
-3.12% | 1.61B | - | ||
+23.78% | 1.21B | B+ | ||
-10.69% | 1.02B | - | ||
-20.89% | 905M | - | C- | |
-7.14% | 716M | - | ||
-18.10% | 682M | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALMKT Stock
- Ratings Mauna Kea Technologies